High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: Early efficacy and impact on quality of life

Blood Transfusion

Volumn 14, Issue 3, 2016, Pages 199-205

  García López, Santiago ^a   Bocos, Judith Millastre ^a   Gisbert, Javier P ^b   Bajador, Eduardo ^a   Chaparro, María ^b   Castaño, Carlos ^b   García Erce, José A ^c   Gomollón, Fernando ^d  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Anaemia Of Chronic Disease; Crohn's Disease; Ferric Carboxymaltose.; Iron Deficiency Aemia; Ulcerative Colitis

Indexed keywords

ALPHA1 GLYCOPROTEIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; FERRIC ION; MALTOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CROHN DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; FLUSHING; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATORY BOWEL DISEASE; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SIBDQ 9 SCORE; SIDE EFFECT; THORAX PAIN; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MALTOSE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; YOUNG ADULT;

EID: 84977079067     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2016.0246-15     Document Type: Article

References (50)

1. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24: 1507-23.
2. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-53.
3. Gisbert JP, Gomollon F. Common. Misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-307.
4. Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 47-52.
5. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123-30.
6. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 250-5.
7. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-7.
8. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334: 619-23.
9. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-91.
10. Kawai M, Sumimoto S, Kasajima Y, et al. A case of ulcerative colitis induced by oral ferrous sulfate. Acta Paediatr Jpn 1992; 34: 476-8.
11. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003; 38: 543-8.
12. Gasche C, Waldhoer T, Feichtenschlager T, et al. Austrian Inflammatory Bowel Diseases Study Group. Prediction of response to iron sucrose in inflammatory bowel disease-Associated anemia. Am J Gastroenterol 2001; 96: 2382-7.
13. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: A randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-9.
14. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-65.
15. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978; 13: 649-56.
16. Bodemar G, Kechagias S, Almer S, et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39: 454-8.
17. Gasche C, Reinisch W, Lochs H, et al. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994; 39: 1930-4.
18. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126: 782-7.
19. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60: 262-7.
20. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-92.
21. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-90.
22. Schroder O, Schrott M, Blumenstein I, et al. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol 2004; 42: 663-7.
23. Van Assche G, Dignass A, Bokemeyer B, et al. European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33.
24. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90.
25. Van Assche G, Dignass A, Panes J, et al. European Crohn's and Colitis Organisation (ECCO) . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
26. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-8.
27. de Dombal FT. Measuring and quantifying the status of patients with inflammatory bowel disease. In: de Dombal FT, Myren J, Bouchier IAD, Watkinson G, editors. Inflammatory bowel disease: some international data and reflections. Oxford: OxfordUniversity Press, 1986. p. 26-95.
28. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
29. WHO, UNICEF, UNU. Iron deficiency anemia: Assessment, prevention and control. A guide for programme managers. Report of a joint WHO/UNICEF/UNU consultation. Geneva: World Health Organization; 1998.
30. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 2004; 116: 44S-9S.
31. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007; 13: 4798-806.
32. Ganzoni AM. [Intravenous iron-dextran: Therapeutic and experimental possibilities]. Schweiz Med Wochenschr 1970; 1007: 301-3. [In German.]
33. López-Vivancos J, Casellas F, Badía X, et al. Validation of the Spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. Digestion 1999; 60: 274-80.
34. Alcalá MJ, Casellas F, Fontanet G, et al. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 383-91.
35. Casellas F, Alcalá MJ, Prieto L, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99: 457-61.
36. Befrits R, Wikman O, Blomquist L, et al. Anemia and iron deficiency in inflammatory bowel disease: An open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol 2013; 48: 1027-32.
37. Evstatiev R, Marteau P, Iqbal T, et al. FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.
38. Evstatiev R, Alexeeva O, Bokemeyer B, et al. FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterology Hepatol 2013; 11: 269-77.
39. Ali M, Rigolosi R, Fayemi AO, et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982; 1: 652-5.
40. Van Wyck DB, Stivelman JC, Ruiz J, et al. Iron status in patients receiving erythropoietin for dialysis-Associated anemia. Kidney Int 1989; 35: 712-6.
41. Gasche C, Evstatiev R, Haas T, et al. Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party. Z Gastroenterol 2011; 49: 627-32.
42. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011; 86: 923-7.
43. Haas JD, Brownlie Tt. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J Nutr 2001; 131: 676S-88S; discussion 88S-90S.
44. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am J Med 2004; 116: 1S-2S.
45. Gasche C. Anemia in IBD: The overlooked villain. Inflamm Bowel Dis 2000; 6: 142-50; discussion 51.
46. Gomollón F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: A practical guide. Drugs 2013; 73: 1761-70.
47. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
48. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose. A review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-56.
49. Macdougall I, Chappell J, Chai MO. Iron supplementation: focus on ferric carboxymaltose. Hospital Pharmacy Europe 2010; 51: 1-4.
50. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Expert Panel on Alternatives to Allogeneic Blood Transfusion. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: The 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.